These data fit with the notion that toxicity of CDK4/6i in patients is generally lower than upon treatment with standard chemotherapy (Klein et al, 2018), and suggest that CDK4/6i could be better tolerated by cancer populations that are at high risk of developing side effects. Here, CDK4 is linked to cancer.